EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope

NCT ID: NCT06340620

Last Updated: 2024-04-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-25

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized trial to compare the standard echoendoscope with the newly developed EndoSound Visual System in the evaluation of lesions in the gastrointestinal tract.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Endoscopic ultrasound (EUS) is the gold standard for evaluation and biopsy of lesions in the pancreaticobiliary tract, subepithelial lesions in the gastrointestinal tract and luminal cancer staging due to its high sensitivity and specificity. Endoscopic ultrasound examination is performed by echoendoscopes, which are endoscopes with an ultrasound probe at the distal end to allow endoscopic ultrasound evaluation. A new endoscopic ultrasound system - the EndoSound Visual System has now been developed for endoscopic ultrasound examination. The EndoSound Visual System is a device that can be attached externally to upper gastrointestinal endoscopes, thereby converting a standard endoscope into an echoendoscope which can then be used to perform an EUS examination.

The aim of this randomized trial is to compare the standard echoendoscope with the newly developed EndoSound Visual System in the evaluation of lesions in the gastrointestinal tract.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Disease Pancreatic Cancer Pancreatic Cyst Gastrointestinal Tumor Bile Duct Diseases Bile Duct Cancer Lymph Node Disease Submucosal Tumor of Gastrointestinal Tract Gastrointestinal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard echoendoscope

Standard echoendoscope will be used and EUS examination will be performed per standard of care.

Group Type ACTIVE_COMPARATOR

Endoscopic ultrasound examination

Intervention Type DEVICE

Endoscopic ultrasound examination will be performed.

EndoSound Vision System

EndoSound Vision System will be used and EUS examination will be performed per standard of care.

Group Type ACTIVE_COMPARATOR

Endoscopic ultrasound examination

Intervention Type DEVICE

Endoscopic ultrasound examination will be performed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Endoscopic ultrasound examination

Endoscopic ultrasound examination will be performed.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Any patient undergoing EUS examination for evaluation of the pancreas, bile duct, mediastinal or intraabdominal lymph nodes, or luminal lesions in the esophagus, stomach, duodenum or colon.

Exclusion Criteria

* Age \< 18 years.
* Unable to obtain consent for the procedure from either the patient or LAR.
* Intrauterine pregnancy.
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Orlando Health, Inc.

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ji Young Bang, MD MPH

Role: PRINCIPAL_INVESTIGATOR

Orlando Health, Digestive Health Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Orlando Health

Orlando, Florida, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ji Young Bang, MD MPH

Role: CONTACT

321-841-2431

Barbara Broome

Role: CONTACT

321-841-4356

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ji Young Bang, MD MPH

Role: primary

321-841-2431

Barbara Broome

Role: backup

321-841-4356

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

24.017.01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Therapeutic EUS Registry
NCT05233631 ENROLLING_BY_INVITATION
SharkCore Versus Acquire FNB
NCT03672032 COMPLETED NA